This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hagan, S. Articles by Kolch, W. Search for Related Content PubMed PubMed Citation Articles by Hagan, S. Articles by Kolch, W.

Reduction of Raf-1 Kinase Inhibitor Protein Expression Correlates with Breast Cancer Metastasis

Authors' Affiliations: ¹ Beatson Institute for Cancer Research, Signaling and Proteomics Laboratory; ² Centre for Oncology and Applied Pharmacology, Cancer Research UK, Beatson Laboratories; ³ Department of Pathology, Western Infirmary; ⁴ Institute of Biomedical and Life Sciences, Sir Henry Wellcome Functional Genomics Facility, University of Glasgow, Glasgow, United Kingdom; ⁵ Molecular Pathology Laboratory, Department of Pathology, Kuwait University, Faculty of Medicine, Safat, Kuwait

Requests for reprints: Walter Kolch, The Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, United Kingdom. Phone: 44-141-330-3983; Fax: 44-141-942-6521; E-mail: wkolch{at}beatson.gla.ac.uk.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Purpose: Raf-1 kinase inhibitor protein (RKIP) was originally identified as the first physiologic inhibitor of the Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (ERK) pathway. This pathway regulates fundamental cellular functions, including those that are subverted in cancer cells, such as proliferation, transformation, survival, and metastasis. Recently, RKIP has been recognized as a strong candidate for a metastasis suppressor gene in cell and animal model systems. Therefore, we investigated whether RKIP expression is altered in clinical specimens of human primary breast cancers and their lymph node metastases.

Experimental Design: Paraffin-embedded tumor samples from 103 breast cancer patients were examined immunohistochemically for the expression of RKIP, activated ERK, and apoptosis. The specificity of the antibodies used was validated by competition experiments with purified recombinant RKIP protein.

Results: RKIP expression was high in breast duct epithelia and retained to varying degrees in primary breast tumors. However, in lymph node metastases, RKIP expression was highly significantly reduced or lost (P = 0.000003). No significant correlations were observed between RKIP expression and histologic type, tumor differentiation grade, size, or estrogen receptor status.

Conclusion: This is the first study of RKIP expression in a large clinical cohort. It confirms the results of cell culture and animal studies, suggesting that in human breast cancer, RKIP is a metastasis suppressor gene whose expression must be down-regulated for metastases to develop. RKIP expression is independent of other markers for breast cancer progression and prognosis.

Originally, RKIP was described as a physiologic endogenous inhibitor protein of the Raf-1/mitogen-activated protein kinase (MAPK) kinase/extracellular signal-regulated kinase (ERK) pathway (5). This pathway is involved in the regulation of many fundamental cellular processes, including proliferation, differentiation, survival, and motility. At its heart is a cascade of three kinases: Raf, which phosphorylates and activates MAPK kinase and MAPK kinase, which phosphorylates and activates ERK, a serine/threonine-specific kinase with >70 known substrates (6, 7). RKIP interferes with the Raf-1-mediated phosphorylation and activation of MAPK kinase via its ability to disrupt the interaction between the two kinases (8). This pathway is altered in 30% of all cancers and has been implicated in invasiveness and metastasis in many in vitro models (9). The ERK pathway is also often hyperactivated in breast cancer (10). Therefore, and in the light of the growing evidence from model systems that RKIP can prevent metastasis, we examined RKIP expression and ERK activation (as measured by staining with phospho-ERK antibody) in 103 clinical samples from patients with metastatic and nonmetastatic breast cancer.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Patient samples. Human breast cancer samples were obtained from 103 patients, including 52 patients without lymph node metastases (henceforth termed node negative) and 51 patients with lymph node metastases (henceforth termed node positive). In the case of node-positive patients, the primary tumor and the corresponding lymph node metastases from the same patient (henceforth termed paired samples) were examined. Samples were obtained from patients following partial or total mastectomy, with informed consent about the use of surgically resected tumors for research purposes, according to the guidelines for research on human tissue and samples set by the University of Glasgow. Parallel samples were processed for in histologic examination by H&E staining. Prognostic indicators of tumor size, grade, histologic type, and estrogen receptor status were subsequently assessed by a breast cancer pathologist (E.M.).

Immunohistochemistry. Sections of formalin-fixed, paraffin-embedded tissue (5 µm) were deparaffinized in two changes of histoclear and rehydrated through graded alcohol to distilled water. Antigen retrieval was done using 0.01 mol/L EDTA buffer (pH 8.0) for RKIP, and 0.01 mol/L citrate buffer (pH 6.0) for phospho-ERK at 95°C for 20 minutes. RKIP protein expression was examined using a 1:1,500 dilution of polyclonal rabbit antibody raised against a recombinant full-length RKIP protein. The expression of phospho-ERK and ERK were detected using commercial rabbit antibodies (Cell Signaling Technology, Inc., Beverly, MA and Santa Cruz Biotechnology, Inc., Santa Cruz, CA, respectively), according to the manufacturer's instructions. Antibody binding was detected using the streptavidin-biotin method (Vector Avidin-Biotin Complex Elite Detection kit, Peterborough, United Kingdom) and 3,3-diaminobenzidine as chromogen (Vector 3,3-Diaminobenzidine Substrate kit). Slides were counterstained with hematoxylin, dehydrated, and mounted. Paraffin-embedded sections of prostate cancer served as positive controls for RKIP expression, and omission of the primary antibody served as negative control. The specificity of the RKIP antibody was assured by (a) replacing it with unrelated IgG and (b) preadsorbing the RKIP antibody with an excess of cognate antigen (recombinant purified RKIP produced in Escherichia coli) before use (Fig. 1).

View larger version (42K): [in this window] [in a new window]   Fig. 1. Specificity of the RKIP antibody. A breast lobule section was stained with an unrelated IgG, RKIP antibody that had been preadsorbed with recombinant RKIP protein (+ competition), or RKIP antibody. Magnification, x200.

Evaluation of immunostaining. All slides were examined and scored by a breast pathologist (E.M.), who was blinded to both clinical and pathologic data. RKIP expression levels were scored using the visual grading system into four classes, whereby 0 = negative, 1 = weak, 2 = moderate, and 3 = intense staining. No score 3 was assigned to RKIP staining in breast cancer samples. Phospho-ERK expression was scored by assessing the average signal intensity (on a scale of 0-3) and the proportion of tumor cells staining positively (0, none; 0.1, 10%; 0.5, 50%; 1.0, >50%). The two scores were multiplied to give an overall H-score, which was considered positive if it was 1.0 (11). Manual scoring was confirmed using digital image analysis by the Zeiss (Thornwood, NY) Axiovision software (Randolph, NJ).

Cell culture and small interfering RNA. MCF-7 cells were maintained in DMEM (Invitrogen Ltd., Paisley, United Kingdom) supplemented with 10% fetal bovine serum at 37°C, 5% CO₂, until use. We purchased an RKIP-specific small interfering RNA (nucleotides 652-672) from Qiagen Ltd. (Crawley, United Kingdom) directed against the following RKIP target sequence (accession no. NM_002567): 5'-CCAGGCCGAGTGGGATGACTA-3'. For small interfering RNA–mediated down-regulation of RKIP, 1 x 10⁶ MCF-7 cells were transfected with a total of 2 µg plasmid DNA using the Nucleofector kit V, according to the manufacturer's instructions (AMAXA Biosystems, Cologne, Germany). Forty-eight hours after transfection, cells were starved in 0.2%FCS/DMEM for 16 hours and treated with 100 ng/mL epidermal growth factor (Roche Diagnostics). Control MCF-7 cells, also underwent serum starvation and epidermal growth factor treatment.

Protein extraction and Western blotting. Total protein extracts from MCF-7 cells were prepared by lysing cells TBS-T buffer [10 mmol/L Tris (pH 7.4), 150 mmol/L NaCl, 1% Triton 100-X], with protease inhibitors (1 mmol/L phenylmethylsulfonyl fluoride, 5 µg/mL leupeptin, 2 mmol/L sodium fluoride, 1.5 µg/mL aprotinin, 0.2 mmol/L sodium pyrophosphate, 10 mmol/L ß-glycerophosphate, and 0.5 mmol/L sodium orthovanadate). Cell extracts were quantified using the bicinchoninic acid protein assay kit (Sigma-Aldrich Co. Ltd., Dorset, United Kingdom), and proteins were separated on SDS-PAGE gels and transferred onto polyvinylidene difluoride membranes. Blots were hybridized with rabbit polyclonal antibodies to RKIP (1:1,000), phospho-ERK, and ERK (all used previously for immunohistochemistry) followed by horseradish peroxidase–conjugated secondary antibodies, and bands were visualized using enhanced chemiluminescence (Amersham Biosciences UK Ltd., Buckinghamshire, United Kingdom).

Statistical analysis. The RKIP expression percentages across the tumor samples determined by the ERK activation (positive/negative) and apoptosis (positive/negative) were compared using the ² test or Fisher's exact test. RKIP expression in the node-positive tumors, and the node-negative tumors was compared using the Mann-Whitney U test. RKIP expression in the primary tumors and the metastases paired groups was compared using the Wilcoxon signed rank test. When applicable, statistical significance is reported. Statistical analysis was done using the SPSS version 11.0 software.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Breast tissue pathology. Histologic typing of primary tumors identified ductal carcinoma as the predominant cancer type, with only occasional presence of other types, such as lobular (n = 4), mucinous (n = 1), cribriform (n = 1), and tubular (n = 3). Tumors ranged in size from 5 to 120 mm (node negative, mean = 19.95 mm) and 6 to 70 mm (node positive, mean = 23.59 mm) and represented all three stages of poorly, moderately, and well differentiated tumors.

Raf-1 kinase inhibitor protein expression in primary breast tumors. All of the primary breast tumors analyzed in this study showed RKIP immunoreactivity, except for one node-negative tumor. RKIP protein was found to be predominantly cytoplasmic, although some nuclear staining was noted. RKIP expression was observed in normal epithelial cells of the milk duct, ductal carcinoma in situ, and cancer cells. RKIP was not detectably expressed in the extracellular matrix or in the connective tissues of breast sections. The RKIP antibody was specific as an unrelated IgG control or RKIP antibody preadsorbed with recombinant RKIP protein produced in E. coli did not result in any staining (Fig. 1).

Intense RKIP staining was observed in normal milk duct epithelial cell, whereas RKIP expression was down-regulated in primary breast carcinomas (Fig. 2). The consistent yet variable down-regulation of RKIP expression in primary breast carcinomas prompted us to examine whether there was a correlation between the reduction of RKIP expression and the propensity to metastasize (Table 1A). In node-positive primary tumors, RKIP expression was moderate in 31 of 51 (60.8%) and weakly positive in 20 of 51 (39.2%) cases. In the node-negative tumors, RKIP expression was moderate in 37 of 52 cases (71.2%), weakly positive in 14 of 52 cases (26.9%), and negative in 1 of 52 cases (1.9%). This distribution of RKIP down-regulation is statistically not significant (P = 0.306) but suggestive of a trend that primary tumors with reduced levels of RKIP expression have a higher tendency to metastasize.

View larger version (29K): [in this window] [in a new window]   Fig. 2. RKIP stain of a section through a mammary ductal adenocarcinoma showing RKIP expression in the milk duct epithelial cells, connective tissue and tumor. Magnification, x400.

View larger version (116K): [in this window] [in a new window]   Fig. 3. RKIP, ERK, and phospho-ERK expression in breast cancer. H&E stain of a node-positive breast carcinoma (A) and the matched lymph node metastasis (D). Immunohistochemical staining shows moderate RKIP immunoreactivity in the primary tumor (B) compared with very faint RKIP staining in the lymph node metastasis (E). Phospho ERK was typically limited to a fraction of the tumor cells (C), whereas nonphosphorylated ERK was expressed in all cells (F). Magnification, x200. In individual cells, RKIP, ERK, and phospho-ERK were detected in the cytoplasm (black arrows), in the nucleus (red arrows), or both compartments (yellow arrows).

Extracellular signal-regulated kinase activation in breast cancer. As RKIP can interfere with ERK activation (5), we assessed the levels of phospho-ERK in the primary tumors and in metastases. ERK activation can be conveniently and quantitatively determined using phosphospecific antibodies that detect the activating phosphorylation sites. All tumors expressed easily detectable and rather uniformly distributed levels of total ERK (i.e., inactive and activated ERK combined; Fig. 3C). In contrast, phospho-ERK staining revealed that activated ERK was not homogeneously distributed, often only found in few tumor cells, interestingly often in cells at the invasive edges of the tumors (Fig. 3F). This staining pattern resulted in low H-scores of <1.0 for most tumors, which were thus deemed negative for phospho-ERK staining. In total, 6 of 50 (12%) node-positive tumors, 4 of 50 (8%) lymph node metastases, and 11 of 51 (21.6%) node-negative tumors reached an H-score of 1 and hence were scored positive for phospho-ERK (Table 2A). In immunopositive tumor cells, phospho-ERK distribution was specific and predominantly nuclear, with occasional cytoplasmic staining (Fig. 3F). Intensity ranged from weak to robust phospho-ERK immunoreactivity, and the proportion of phospho-ERK positive cancer cells varied between <5% and >80%.

Raf-1 kinase inhibitor protein enhances apoptosis in node-negative tumors. RKIP can sensitize prostate and breast carcinoma cells to drug-induced apoptosis (4). Therefore, we assessed the levels of apoptosis in a subset of 21 tumors from node-negative and node-positive groups, including paired lymph node metastases, and compared them with RKIP expression (Table 2B). No significant difference between RKIP expression and apoptosis was noted for node-positive tumors or for paired lymph node metastases. However, a statistically significant weak association between RKIP expression and apoptosis was found in node-negative tumors (Fisher's exact test, P = 0.042). This suggests that the role of RKIP to prevent metastasis may be associated with the ability to promote apoptosis.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
In this study, we show that RKIP expression is significantly reduced in lymph node metastases of breast cancers. Previous studies with cultured tumor cells derived from melanoma, prostate, and breast cancers have indicated that RKIP is a strong candidate for a metastasis suppressor gene (2–4). Here, we present the first larger-scale study on clinical material from 103 breast cancer patients. Our results fully support the conclusion that RKIP is a metastasis suppressor gene, as its expression is consistently lost in lymph node metastases but not in primary tumors. Importantly, RKIP is independent of other established clinical markers, such as histologic type, tumor differentiation grade, size, or estrogen receptor status.

Our study also suggests that the requirement for a metastatic cell to reduce or lose RKIP expression is not only related to RKIP's inhibitory effect on the ERK pathway. Previous studies done in cell culture and animal models have shown that metastatic prostate cancer and melanoma cells feature elevated levels of phospho-ERK and reduced RKIP expression. Restoration of RKIP expression by exogenous expression decreased phospho-ERK levels as well as invasive behavior (2–4). However, in human breast cancer sections, ERK activation was observable in only a small number of tumors in our patient cohort and usually only in a fraction of tumor cells. ERK has been reported to be activated in breast tumors, but these results are mostly based on examining homogenized tumor tissue by Western blotting rather than by immunohistochemistry with single-cell resolution on tissue sections (10). Two recent studies have shown that ERK activation correlates with a less aggressive tumor phenotype and better survival (12, 13). Although the reasons for these discrepancies are unclear at present, in the current study, we observed that reduction in RKIP expression did not lead to activation of ERK in primary tumors or metastases. This observation could suggest that the chronic hyperactivation of ERK triggers strong feedback mechanisms that in conjunction with even low RKIP expression suffice to reduce ERK activation below the levels detectable by immunohistochemistry. ERK activation can initiate multiple feedback mechanisms, including the expression of phosphatases (MAPK phosphatases) that inactivate ERKs, and may be responsible for the poor responsiveness of ERK to mitogen activation in many cancer cell lines (14).

A more intriguing interpretation could be that RKIP, in addition to the regulation of the ERK pathway, fulfils another yet unknown function that impedes metastasis. A lead is provided by the finding that node-negative tumors exhibited a statistically significant but weak correlation between RKIP expression and apoptosis (Table 2B). It has been shown that RKIP also can inhibit the activation of the nuclear factor-B (NF-B) transcription factor by interfering with the degradation of its inhibitor IB (15). NF-B exerts a potent antiapoptotic function, is required for the development of the mammary gland, and promotes metastasis in mouse models for breast cancer (16–18). In MCF7 breast carcinoma cell lines, the down-regulation of RKIP by small interfering RNA did not affect the activation of ERK but enhanced the phosphorylation and degradation of IB (data not shown), suggesting that the reduction of RKIP expression in mammary tumors activates the NF-B pathway. We have tried to examine the status of NF-B signaling in our set of breast carcinomas, but unfortunately, none of the antibodies tested (i.e., anti-IB, anti-phospho-IB, anti-p50, or anti-p65 NF-B) did well in immunohistochemistry. Thus, although NF-B certainly is a candidate, the question as to what constitutes the RKIP target relevant for metastasis needs reevaluation. We are currently addressing this question by the systematic identification of RKIP binding partners through the proteomic analysis of RKIP multiprotein complexes.

Regardless of the exact mechanism of RKIP function, the highly significant down-regulation of RKIP expression in metastases and the apparent lack of mutations in the RKIP coding sequence (2) could provide a new therapeutic target for the treatment of metastatic cancer. Preliminary observations show that RKIP protein expression can be induced by ionizing radiation⁶ or by chemotherapeutic drugs (4). As both regimens are part of the current clinical armory, it will be worthwhile to explore whether RKIP reexpression contributes to their therapeutic efficacy.

	Acknowledgments

 
We thank Oliver Rath (Signaling and Proteomics Laboratory, Beatson Institute for Cancer Research, Glasgow, UK) for kindly supplying the small interfering RNA/RKIP oligonucleotide, Margaret O'Prey and Iain Downey for technical advice, Issam Francis for assistance with the terminal deoxynucleotidyl transferase–mediated nick-end labeling assessments, and Mark Montgomery (Zeiss) for the image analysis with the Axiovision software.

	Footnotes

 
Grant support: Association for International Cancer Research grant 02-141 (S. Hagan and W. Kolch), Kuwait Foundation for the Advancement of Sciences grant 99-07-07 (F. Al-Mulla), Kuwait University shared facility grant GM/0101 (F. Al-Mulla), and Cancer Research UK core grant Beatson (W. Kolch).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: No author has conflict of interests regarding this work.

⁶ A. Dhillon and W.K. Olch, unpublished data.

Received 2/ 7/05; revised 6/27/05; accepted 7/26/05.

	References

Top Abstract Materials and Methods Results Discussion References

 

1. Shevde LA, Welch DR. Metastasis suppressor pathways: an evolving paradigm. Cancer Lett 2003;198:1–20.[CrossRef][Medline]
2. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 2004;64:5186–92.[Abstract/Free Full Text]
3. Fu Z, Smith PC, Zhang L, et al. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003;95:878–89.[Abstract/Free Full Text]
4. Chatterjee D, Bai Y, Wang Z, et al. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 2004;279:17515–23.[Abstract/Free Full Text]
5. Yeung K, Seitz T, Li S, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999;401:173–7.[CrossRef][Medline]
6. Kolch W. Ras/Raf signalling and emerging pharmacotherapeutic targets. Expert Opin Pharmacother 2002;3:709–18.[CrossRef][Medline]
7. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004;5:875–85.[CrossRef][Medline]
8. Yeung K, Janosch P, McFerran B, et al. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 2000;20:3079–85.[Abstract/Free Full Text]
9. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 2003;22:395–403.[CrossRef][Medline]
10. Santen RJ, Song RX, McPherson R, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002;80:239–56.[CrossRef][Medline]
11. Al Haddad S, Zhang Z, Leygue E, et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 1999;155:2057–66.[Abstract/Free Full Text]
12. Svensson S, Jirstrom K, Ryden L, et al. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 2005;24:4370–9.[CrossRef][Medline]
13. Milde-Langosch K, Bamberger AM, Rieck G, et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 2005;20:2206–15.
14. Shapiro PS, Ahn NG. Feedback regulation of Raf-1 and mitogen-activated protein kinase (MAP) kinase kinases 1 and 2 by MAP kinase phosphatase-1 (MKP-1). J Biol Chem 1998;273:1788–93.[Abstract/Free Full Text]
15. Yeung KC, Rose DW, Dhillon AS, et al. Raf kinase inhibitor protein interacts with NF-B-inducing kinase and TAK1 and inhibits NF-B activation. Mol Cell Biol 2001;21:7207–17.[Abstract/Free Full Text]
16. Huber MA, Azoitei N, Baumann B, et al. NF-B is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004;114:569–81.[CrossRef][Medline]
17. Cao Y, Karin M. NF-B in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003;8:215–23.[CrossRef][Medline]
18. Helbig G, Christopherson KW, Bhat-Nakshatri P, et al. NF-B promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003;278:21631–8.[Abstract/Free Full Text]

This article has been cited by other articles:

				H. Z. Li, Y. Wang, Y. Gao, J. Shao, X. L. Zhao, W. M. Deng, Y. X. Liu, J. Yang, and Z. Yao Effects of Raf Kinase Inhibitor Protein Expression on Metastasis and Progression of Human Epithelial Ovarian Cancer Mol. Cancer Res., June 1, 2008; 6(6): 917 - 928. [Abstract] [Full Text] [PDF]

				D. Chatterjee, E. Sabo, R. Tavares, and M. B. Resnick Inverse Association between Raf Kinase Inhibitory Protein and Signal Transducers and Activators of Transcription 3 Expression in Gastric Adenocarcinoma Patients: Implications for Clinical Outcome Clin. Cancer Res., May 15, 2008; 14(10): 2994 - 3001. [Abstract] [Full Text] [PDF]

				F Al-Mulla, S Hagan, W Al-Ali, S P Jacob, A I Behbehani, M S Bitar, A Dallol, and W Kolch Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability J. Clin. Pathol., April 1, 2008; 61(4): 524 - 529. [Abstract] [Full Text] [PDF]

				I. Zlobec, K. Baker, P. Minoo, J. R. Jass, L. Terracciano, and A. Lugli Node-Negative Colorectal Cancer at High Risk of Distant Metastasis Identified by Combined Analysis of Lymph Node Status, Vascular Invasion, and Raf-1 Kinase Inhibitor Protein Expression Clin. Cancer Res., January 1, 2008; 14(1): 143 - 148. [Abstract] [Full Text] [PDF]

				F. Al-Mulla, S. Hagan, A. I. Behbehani, M. S. Bitar, S. S. George, J. J. Going, J. J. C. Garcia, L. Scott, N. Fyfe, G. I. Murray, et al. Raf Kinase Inhibitor Protein Expression in a Survival Analysis of Colorectal Cancer Patients J. Clin. Oncol., December 20, 2006; 24(36): 5672 - 5679. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hagan, S. Articles by Kolch, W. Search for Related Content PubMed PubMed Citation Articles by Hagan, S. Articles by Kolch, W.